Affimed (NASDAQ:AFMD) Short Interest Down 14.9% in March

Affimed (NASDAQ:AFMD) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 602,500 shares, a drop of 14.9% from the February 28th total of 708,100 shares. Based on an average trading volume of 186,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 4.6% of the company’s stock are short sold.

Affimed Price Performance

NASDAQ AFMD opened at $0.72 on Tuesday. The firm’s fifty day simple moving average is $0.98 and its two-hundred day simple moving average is $2.06. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 12-month low of $0.72 and a 12-month high of $8.95.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AFMD. Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Affimed in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AFMD. Jane Street Group LLC purchased a new stake in Affimed in the third quarter valued at about $44,000. FMR LLC increased its holdings in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares in the last quarter. Intellectus Partners LLC raised its position in shares of Affimed by 34.0% in the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 32,053 shares during the last quarter. Northern Trust Corp acquired a new stake in Affimed in the 4th quarter worth approximately $218,000. Finally, Point72 Asset Management L.P. grew its position in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the last quarter. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.